-
1
-
-
34548488202
-
Epidemiology of staphylococcal resistance
-
Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007;45(suppl 3):S171-6.
-
(2007)
Clin Infect Dis
, vol.45
, Issue.3 SUPPL.
-
-
Shorr, A.F.1
-
2
-
-
31044456290
-
Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in U.S. hospitals, 1992-2003
-
Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in U.S. hospitals, 1992-2003. Clin Infect Dis 2006;42:389-391
-
(2006)
Clin Infect Dis
, vol.42
, pp. 389-391
-
-
Klevens, R.M.1
Edwards, J.R.2
Tenover, F.C.3
McDonald, L.C.4
Horan, T.5
Gaynes, R.6
-
3
-
-
44149101032
-
Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains
-
Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46(suppl 5):S360-7.
-
(2008)
Clin Infect Dis
, vol.46
, Issue.5 SUPPL.
-
-
Sakoulas, G.1
Moellering Jr., R.C.2
-
4
-
-
58749108809
-
Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005
-
Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009;48:e23-33.
-
(2009)
Clin Infect Dis
, vol.48
-
-
Richter, S.S.1
Heilmann, K.P.2
Dohrn, C.L.3
Riahi, F.4
Beekmann, S.E.5
Doern, G.V.6
-
5
-
-
68049093117
-
Increase in pneumococcus macrolide resistance, United States
-
Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009;15:1260-1264
-
(2009)
Emerg Infect Dis
, vol.15
, pp. 1260-1264
-
-
Jenkins, S.G.1
Farrell, D.J.2
-
6
-
-
60649089374
-
Susceptibilites of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics
-
Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R. Susceptibilites of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009;63:511-519
-
(2009)
J Antimicrob Chemother
, vol.63
, pp. 511-519
-
-
Harrison, C.J.1
Woods, C.2
Stout, G.3
Martin, B.4
Selvarangan, R.5
-
7
-
-
77950434744
-
-
Activity of ceftaroline against emerging serotypes of Streptococcus pneumoniae Poster presentation at
-
Jacobs MR, Bajaksouzian S, Windau A, et al. Activity of ceftaroline against emerging serotypes of Streptococcus pneumoniae. Poster presentation at 49th annual interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 12-15, 2009.
-
49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009
-
-
Jacobs, M.R.1
Bajaksouzian, S.2
Windau, A.3
-
8
-
-
34249906193
-
Counterpoint: Vancomycin and Staphylococcus aureus: an antibiotic enters obsolescence
-
Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus: an antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543-1548
-
(2007)
Clin Infect Dis
, vol.44
, pp. 1543-1548
-
-
Deresinski, S.1
-
9
-
-
50949085411
-
Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin
-
Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-3320
-
(2008)
Antimicrob Agents Chemother
, vol.52
, pp. 3315-3320
-
-
Lodise, T.P.1
Graves, J.2
Evans, A.3
-
10
-
-
39449112495
-
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia
-
Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
-
(2008)
Clin Infect Dis
, vol.46
, pp. 193-200
-
-
Soriano, A.1
Marco, F.2
Martinez, J.A.3
-
11
-
-
34447278781
-
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia
-
Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:2582-2586
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 2582-2586
-
-
Moise, P.A.1
Sakoulas, G.2
Forrest, A.3
Schentag, J.J.4
-
12
-
-
33750285524
-
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity
-
Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-2144
-
(2006)
Arch Intern Med
, vol.166
, pp. 2138-2144
-
-
Hidayat, L.K.1
Hsu, D.I.2
Quist, R.3
Shriner, K.A.4
Wong-Beringer, A.5
-
13
-
-
2942558870
-
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia
-
Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402
-
(2004)
J Clin Microbiol
, vol.42
, pp. 2398-2402
-
-
Sakoulas, G.1
Moise-Broder, P.A.2
Schentag, J.3
Forrest, A.4
Moellering Jr., R.C.5
Eliopoulos, G.M.6
-
14
-
-
12444281009
-
TAK-599, a novel N-phosphono-type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties
-
Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono-type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003;11:2427-2437
-
(2003)
Bioorg Med Chem
, vol.11
, pp. 2427-2437
-
-
Ishikawa, T.1
Matsunaga, N.2
Tawada, H.3
-
15
-
-
54349094745
-
Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono-type prodrug of anti-methicillin-resistant Staphylococcus aureus cephalosporin T-91825
-
Ikeda Y, Ban J, Ishikawa T, Hashiguchi S, Urayama S, Horibe H. Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono-type prodrug of anti-methicillin-resistant Staphylococcus aureus cephalosporin T-91825. Chem Pharm Bull 2008;56:1406-1411
-
(2008)
Chem Pharm Bull
, vol.56
, pp. 1406-1411
-
-
Ikeda, Y.1
Ban, J.2
Ishikawa, T.3
Hashiguchi, S.4
Urayama, S.5
Horibe, H.6
-
16
-
-
47749154496
-
Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: Potent inhibition of PBP2a by two anti-MRSA β-lactam antibiotics
-
Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP2a by two anti-MRSA β-lactam antibiotics. J Am Chem Soc 2008;130:9212-9213
-
(2008)
J Am Chem Soc
, vol.130
, pp. 9212-9213
-
-
Villegas-Estrada, A.1
Lee, M.2
Hesek, D.3
Vakulenko, S.B.4
Mobashery, S.5
-
17
-
-
77950390822
-
-
Binding of ceftaroline (CPT) to penicillin-binding proteins (PBPs) of Streptococcus pneumoniae (SPN) and methicillin-resistant Staphylococcus aureus (MRSA). Poster presentation at
-
Moisan HPM, Malouin F. Binding of ceftaroline (CPT) to penicillin-binding proteins (PBPs) of Streptococcus pneumoniae (SPN) and methicillin-resistant Staphylococcus aureus (MRSA). Poster presentation at 48th annual interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Moisan, H.P.M.1
Malouin, F.2
-
18
-
-
23044471735
-
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
-
Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49:3501-3512
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 3501-3512
-
-
Sader, H.S.1
Fritsche, T.R.2
Kaniga, K.3
Ge, Y.4
Jones, R.N.5
-
19
-
-
50949105050
-
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States
-
Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52:3398-3407
-
(2008)
Antimicrob Agents Chemother
, vol.52
, pp. 3398-3407
-
-
Ge, Y.1
Biek, D.2
Talbot, G.H.3
Sahm, D.F.4
-
20
-
-
64549135399
-
Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia
-
Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009;33:515-519
-
(2009)
Int J Antimicrob Agents
, vol.33
, pp. 515-519
-
-
Morrissey, I.1
Ge, Y.2
Janes, R.3
-
21
-
-
77950398872
-
-
Antimicrobial activity of ceftaroline tested against contemporary (2008) bacteria isolated from community-acquired respiratory tract infections (CARTI), including oxacillin- (methicillin-) resistant Staphylococcus aureus. Poster presentation at the
-
Sader HS, Jones RN. Antimicrobial activity of ceftaroline tested against contemporary (2008) bacteria isolated from community-acquired respiratory tract infections (CARTI), including oxacillin- (methicillin-) resistant Staphylococcus aureus. Poster presentation at the Staphylococcus symposium, Honolulu, HI, March 11-14, 2009.
-
Staphylococcus Symposium, Honolulu, HI, March 11-14, 2009
-
-
Sader, H.S.1
Jones, R.N.2
-
22
-
-
77950438701
-
-
Ceftaroline activity against organisms causing skin and skin-structure infections (SSSI) isolated in U.S. and European medical centers in 2008. Poster presentation at the
-
Jones RN, Fritsche TR, Sader HS. Ceftaroline activity against organisms causing skin and skin-structure infections (SSSI) isolated in U.S. and European medical centers in 2008. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Jones, R.N.1
Fritsche, T.R.2
Sader, H.S.3
-
23
-
-
40549135961
-
Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus
-
Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:1153-1155
-
(2008)
Antimicrob Agents Chemother
, vol.52
, pp. 1153-1155
-
-
Sader, H.S.1
Fritsche, T.R.2
Jones, R.N.3
-
24
-
-
77950450275
-
-
In vitro activity of ceftaroline agains CA-MRSA, VISA, VRSA, and daptomycin-nonsusceptible Staphylococcus aureus (DNSSA). Poster presentation at the
-
Saravolatz LD, Pawlak J, Johnson L. In vitro activity of ceftaroline agains CA-MRSA, VISA, VRSA, and daptomycin-nonsusceptible Staphylococcus aureus (DNSSA). Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Saravolatz, L.D.1
Pawlak, J.2
Johnson, L.3
-
25
-
-
55849104841
-
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime
-
Fenoll A, Aguilar L, Robledo O, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008;52:4209-4210
-
(2008)
Antimicrob Agents Chemother
, vol.52
, pp. 4209-4210
-
-
Fenoll, A.1
Aguilar, L.2
Robledo, O.3
-
26
-
-
59749096800
-
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae
-
McGee L, Biek D, Ge Y, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009;53:552-556
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 552-556
-
-
McGee, L.1
Biek, D.2
Ge, Y.3
-
27
-
-
77950410921
-
-
Activities of ceftaroline, ceftibiprole, and cethromycin against multi-drug resistant (MDR) Streptococcus pneumoniae isolates from Canadian bacterial surveillance network (CBSN). Poster presentation at
-
Patel SN, McGeer A, Green K, Pong-Porter S, Low DE. Activities of ceftaroline, ceftibiprole, and cethromycin against multi-drug resistant (MDR) Streptococcus pneumoniae isolates from Canadian bacterial surveillance network (CBSN). Poster presentation at 48th annual interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Patel, S.N.1
McGeer, A.2
Green, K.3
Pong-Porter, S.4
Low, D.E.5
-
28
-
-
77950390032
-
-
In vitro activity of ceftaroline (CPT) against recent U.S. isolates of Neisseria gonorrhoeae. Poster presentation at the
-
Barry PM, Lenderman CJ, Melendez JH, et al. In vitro activity of ceftaroline (CPT) against recent U.S. isolates of Neisseria gonorrhoeae. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Barry, P.M.1
Lenderman, C.J.2
Melendez, J.H.3
-
29
-
-
34547841550
-
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes
-
Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-311
-
(2007)
J Antimicrob Chemother
, vol.60
, pp. 300-311
-
-
Mushtaq, S.1
Warner, M.2
Ge, Y.3
Kaniga, K.4
Livermore, D.M.5
-
30
-
-
77950456676
-
-
AmpC induction by ceftaroline. Poster presentation at
-
Mushtaq S, Livermore DM. AmpC induction by ceftaroline. Poster presentation at 49th annual interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 12-15, 2009.
-
49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009
-
-
Mushtaq, S.1
Livermore, D.M.2
-
31
-
-
77950440557
-
-
Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline. Poster presentation at the
-
Hinshaw RR, Schaadt RD, Murray B, et al. Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline. Poster presentation at the 48th inter-science conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Inter-science Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Hinshaw, R.R.1
Schaadt, R.D.2
Murray, B.3
-
32
-
-
77950440999
-
-
In vitro evaluation of the antibacterial activity of ceftaroline in combination with other antibacterial agents. Poster presentation at the
-
Schaadt RD, Sweeney DA, Biek D, Zurenko GE. In vitro evaluation of the antibacterial activity of ceftaroline in combination with other antibacterial agents. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
-
47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007
-
-
Schaadt, R.D.1
Sweeney, D.A.2
Biek, D.3
Zurenko, G.E.4
-
33
-
-
77950426430
-
-
In vitro activity and aminoglycoside synergy of ceftaroline (CPT) against clinical isolates of hospital-acquired (HA) methicillin-resistant Staphylococcus aureus (MRSA). Poster presentation at
-
Vidaillac C, Leonard SN, Rybak M. In vitro activity and aminoglycoside synergy of ceftaroline (CPT) against clinical isolates of hospital-acquired (HA) methicillin-resistant Staphylococcus aureus (MRSA). Poster presentation at 48th annual interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Vidaillac, C.1
Leonard, S.N.2
Rybak, M.3
-
34
-
-
67049086953
-
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa
-
Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53:2360-2366
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 2360-2366
-
-
Vidaillac, C.1
Leonard, S.N.2
Sader, H.S.3
Jones, R.N.4
Rybak, M.J.5
-
35
-
-
77950453119
-
-
Effects of in vitro test method variables on ceftaroline activity aerobic gram-positive and gram-negative pathogens. Poster presentation at the
-
Citron DM, Goldstein EJC. Effects of in vitro test method variables on ceftaroline activity aerobic gram-positive and gram-negative pathogens. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Citron, D.M.1
Goldstein, E.J.C.2
-
36
-
-
29444443515
-
Evaluation of PPI-0903M (T91825), a novel cephalosporin: Bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests
-
Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005;56:1047-1052
-
(2005)
J Antimicrob Chemother
, vol.56
, pp. 1047-1052
-
-
Jones, R.N.1
Fritsche, T.R.2
Ge, Y.3
Kaniga, K.4
Sader, H.S.5
-
37
-
-
62949159531
-
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing
-
Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009;53:1271-1274
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 1271-1274
-
-
Brown, S.D.1
Traczewski, M.M.2
-
38
-
-
77950428234
-
-
Ceftaroline: quality control limits for minimum inhibitory concentration (MIC) and disk diffusion susceptibility testing. Poster presentation at the
-
Brown SD, Traczewski MM. Ceftaroline: quality control limits for minimum inhibitory concentration (MIC) and disk diffusion susceptibility testing. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
-
47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007
-
-
Brown, S.D.1
Traczewski, M.M.2
-
39
-
-
77950447003
-
-
Ceftaroline: in vitro potency, spectrum of activity, MIC and disk diffusion breakpoints. Poster presentation at the
-
Brown SD, Traczewski MM. Ceftaroline: in vitro potency, spectrum of activity, MIC and disk diffusion breakpoints. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
-
47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007
-
-
Brown, S.D.1
Traczewski, M.M.2
-
40
-
-
77950438188
-
-
Comparative evaluation of ceftaroline MIC testing with Etest and CLSI broth microdilution methods. Poster presentation at the
-
Engelhardt A, Yusof A, Ho P, Sjostrom K, Johansson C. Comparative evaluation of ceftaroline MIC testing with Etest and CLSI broth microdilution methods. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Engelhardt, A.1
Yusof, A.2
Ho, P.3
Sjostrom, K.4
Johansson, C.5
-
41
-
-
77950421170
-
-
In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M). Poster presentation at the
-
Ge JY, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M). Poster presentation at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
-
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006
-
-
Ge, J.Y.1
Hubbel, A.2
-
42
-
-
77950410073
-
-
Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. Poster presentation at the
-
Ge JY, Redman R, Floren L, Liao S, Wikler M. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. Poster presentation at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
-
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006
-
-
Ge, J.Y.1
Redman, R.2
Floren, L.3
Liao, S.4
Wikler, M.5
-
43
-
-
77950407216
-
-
Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI). Poster presentation at the
-
Ge JY, Thye DA, Liao S, Talbot GH. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI). Poster presentation at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
-
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006
-
-
Ge, J.Y.1
Thye, D.A.2
Liao, S.3
Talbot, G.H.4
-
44
-
-
77950425287
-
-
The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving mulitple-dose intravenous (IV) infusions. Poster presentation at the
-
Ge JY, Redman R, Floren L, Liao S, Wikler M. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving mulitple-dose intravenous (IV) infusions. Poster presentation at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
-
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006
-
-
Ge, J.Y.1
Redman, R.2
Floren, L.3
Liao, S.4
Wikler, M.5
-
45
-
-
77950423266
-
-
Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infections (cSSSI). Poster presentation at the
-
Ge JY, Liao S, Talbot GH. Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infections (cSSSI). Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
-
47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007
-
-
Ge, J.Y.1
Liao, S.2
Talbot, G.H.3
-
46
-
-
77950384829
-
-
An open-label, pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis. Poster presentation at the
-
Riccobene T, Jakate A, Rank D, Thye DA. An open-label, pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis. Poster presentation at the European congress of clinical microbiology and infectious diseases, Helsinki, Finland, May 16-19, 2009.
-
European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16-19, 2009
-
-
Riccobene, T.1
Jakate, A.2
Rank, D.3
Thye, D.A.4
-
47
-
-
77950454868
-
-
Comparative pharmacokinetics (PK) of ceftaroline (CPT) in rats, rabbits, and monkeys following a single intramuscular (IM) or intravenous (IV) injection. Poster presentation at the
-
Ge JY, Maynard D, Rickert DE. Comparative pharmacokinetics (PK) of ceftaroline (CPT) in rats, rabbits, and monkeys following a single intramuscular (IM) or intravenous (IV) injection. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Ge, J.Y.1
Maynard, D.2
Rickert, D.E.3
-
48
-
-
77950379247
-
-
A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. Poster presentation at the
-
Riccobene T, Fang E, Thye DA. A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Riccobene, T.1
Fang, E.2
Thye, D.A.3
-
49
-
-
33645766499
-
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: Identification of an in vivo pharmacokinetic-pharmacodynamic target
-
Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006;50:1376-1383
-
(2006)
Antimicrob Agents Chemother
, vol.50
, pp. 1376-1383
-
-
Andes, D.1
Craig, W.A.2
-
50
-
-
77950450276
-
-
Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI). Poster presentation at the
-
Ge JY, Liao S, Thye DA, Talbot GH. Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI). Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
-
47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007
-
-
Ge, J.Y.1
Liao, S.2
Thye, D.A.3
Talbot, G.H.4
-
51
-
-
3843081646
-
In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599
-
Iizawa Y, Nagai J, Ishikawa T, et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004;10:146-156
-
(2004)
J Infect Chemother
, vol.10
, pp. 146-156
-
-
Iizawa, Y.1
Nagai, J.2
Ishikawa, T.3
-
52
-
-
77950396259
-
-
Real-time evaluation of ceftaroline, a new cephalosporin, vs vancomycin & daptomycin in a rat S. aureus endocarditis model using in vivo bioluminescent imaging. Poster presentation at the
-
Xiong YQ, Li Y, Abdelsayed GA, Biek D, Bayer AS. Real-time evaluation of ceftaroline, a new cephalosporin, vs vancomycin & daptomycin in a rat S. aureus endocarditis model using in vivo bioluminescent imaging. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
-
47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007
-
-
Xiong, Y.Q.1
Li, Y.2
Abdelsayed, G.A.3
Biek, D.4
Bayer, A.S.5
-
53
-
-
77950430248
-
-
Assessment of the in vivo activity of ceftaroline (CPT) against vancomycin-susceptible and -resistant Enterococcus faecalis (EF) strains in a rabbit endocarditis model (REM): comparison with linezolid (LZO) and vancomycin (VAN). Poster presentation at the
-
Jacqueline C, Amador G, Batard E, et al. Assessment of the in vivo activity of ceftaroline (CPT) against vancomycin-susceptible and -resistant Enterococcus faecalis (EF) strains in a rabbit endocarditis model (REM): comparison with linezolid (LZO) and vancomycin (VAN). Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Jacqueline, C.1
Amador, G.2
Batard, E.3
-
54
-
-
77950409477
-
-
Evaluation of the efficacy of intramuscular (IM) administration of ceftaroline (CPT) against a methicillin-resistant Staphylococcus aureus (MRSA) strain in a rabbit endocarditis model (REM). Poster presentation at the
-
Jacqueline C, Caillon J, Le Mabecque V, et al. Evaluation of the efficacy of intramuscular (IM) administration of ceftaroline (CPT) against a methicillin-resistant Staphylococcus aureus (MRSA) strain in a rabbit endocarditis model (REM). Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Jacqueline, C.1
Caillon, J.2
Le Mabecque, V.3
-
55
-
-
35948962693
-
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate
-
Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007;51:3397-3400
-
(2007)
Staphylococcus Aureus in a Rabbit Endocarditis Model. Antimicrob Agents Chemother
, vol.51
, pp. 3397-3400
-
-
Jacqueline, C.1
Caillon, J.2
Le Mabecque, V.3
-
56
-
-
77950445600
-
-
In vivo assessment of the activity of ceftaroline, linezolid, and vancomycin in a rabbit osteomyelitis experimental model due to MRSA and GISA. Poster presentation at the
-
Jacqueline C, Caillon J, Amador G, et al. In vivo assessment of the activity of ceftaroline, linezolid, and vancomycin in a rabbit osteomyelitis experimental model due to MRSA and GISA. Poster presentation at the American College of Clinical Pharmacy spring practice and research forum, Phoenix, AZ, April 5-9, 2008.
-
American College of Clinical Pharmacy Spring Practice and Research Forum, Phoenix, AZ, April 5-9, 2008
-
-
Jacqueline, C.1
Caillon, J.2
Amador, G.3
-
57
-
-
34948854764
-
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections
-
Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-3616
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 3612-3616
-
-
Talbot, G.H.1
Thye, D.2
Das, A.3
Ge, Y.4
-
58
-
-
77950400814
-
-
CANVAS-2: randomized, double-blinded, phase 3 study (P903-07) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections. Poster presentation at the
-
Wilcox M, Corey GR, Talbot GH, Baculik T, Thye DA. CANVAS-2: randomized, double-blinded, phase 3 study (P903-07) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections. Poster presentation at the European congress of clinical microbiology and infectious diseases, Helsinki, Finland, May 16-19, 2009.
-
European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16-19, 2009
-
-
Wilcox, M.1
Corey, G.R.2
Talbot, G.H.3
Baculik, T.4
Thye, D.A.5
-
59
-
-
77950376750
-
-
CANVAS-1: randomized, double-blinded, phase 3 study (P903-06) of the efficacy and safety of ceftaroline vs. vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI). Poster presentation at the
-
Corey GR, Wilcox M, Talbot GH, Baculik T, Thye DA. CANVAS-1: randomized, double-blinded, phase 3 study (P903-06) of the efficacy and safety of ceftaroline vs. vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI). Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy-46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
-
48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008
-
-
Corey, G.R.1
Wilcox, M.2
Talbot, G.H.3
Baculik, T.4
Thye, D.A.5
-
60
-
-
77950431697
-
-
U.S. National Institutes of Health. Available from Accessed November 23, 2009
-
U.S. National Institutes of Health. ClinicalTrials.gov. Available from http://clinicaltrials.gov/ct2/results?term=ceftaroline. Accessed November 23, 2009.
-
-
-
-
61
-
-
77950444299
-
-
FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). Poster presentation at the
-
Eckburg P, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA. FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). Poster presentation at the 49th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 12-15, 2009.
-
49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009
-
-
Eckburg, P.1
Friedland, H.D.2
Lee, J.3
Llorens, L.4
Critchley, I.A.5
Thye, D.A.6
|